The global atrial fibrillation devices market is estimated to grow significantly at a CAGR of 13.7% during the forecast period. The major factors contributing to the market growth include rising prevalence of atrial fibrillation coupled with the significant incidences of cardiac arrhythmias and rising demand for minimally invasive procedures. Atrial fibrillation is the most common cause of heart arrhythmia, in which, the heart beats very slowly, very fast or in an irregular way. According to the Institute for Health Metrics and Evaluation, the prevalence of atrial fibrillation in 2013 was 33.6 million, which increased up to 37.5 million in 2017. With the significant rise in geriatric population across the globe, this number is expected to increase in the near future.
The two major strategies used for the management of atrial fibrillation include rhythm control and rate control. Rhythm control comprises the use of electrophysiological interventions which intends to convert the arrhythmia concerned with atrial fibrillation to normal sinus rhythm. While diagnosed with atrial fibrillation, the doctor recommends an electrophysiology study to better understand the way electrical signals move in the heart to make it beat. The test enables to understand and map the electrical activity in the heart, which, in turn, contributes to diagnose abnormal heart rhythms.
Segmental Outlook
The global atrial fibrillation devices market is segmented on the basis of product type, end-use, and region. On the basis of product type, the market is sub-segmented into electrophysiology ablation catheters, electrophysiology diagnostic catheters, electrophysiology mapping and recording systems, cardiac monitors, and others. Based on the end-use, the market is divided into hospitals and ambulatory surgery centers (ASCs).
Global Atrial Fibrillation Devices Market Share by End-Use, 2018 (%)
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Abbott Laboratories Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Boston Scientific Corp.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Koninklijke Philips NV
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Siemens AG
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Medtronic PLC
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Atrial Fibrillation Devices Market by Product Type
5.1.1. Electrophysiology Ablation Catheters
5.1.2. Electrophysiology Diagnostic Catheters
5.1.3. Electrophysiology Mapping and Recording Systems
5.1.4. Cardiac Monitors
5.1.5. Others (Intracardiac Echocardiography (ICE) Systems)
5.2. Global Atrial Fibrillation Devices Market by End-Use
5.2.1. Hospitals and Clinics
5.2.2. Ambulatory Surgery Centers (ASCs)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. Japan
6.3.3. India
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott Laboratories Inc.
7.2. Advanced Cardiac Therapeutics, Inc.
7.3. AliveCor, Inc.
7.4. AtriCure, Inc.
7.5. AuriGen Medical
7.6. BIOTRONIK SE & Co. KG
7.7. Boston Scientific Corp.
7.8. CardioFocus, Inc.
7.9. CathRx Ltd.
7.10. General Electric Co.
7.11. Hansen Medical Inc.
7.12. Japan Lifeline Co.
7.13. Johnson and Johnson Services Inc. (Biosense Webster)
7.14. Koninklijke Philips NV
7.15. Medtronic PLC
7.16. MicroPort Scientific Corp.
7.17. Osypka AG
7.18. Siemens AG
7.19. Stereotaxis, Inc.
7.20. Vanguard AG
7.21. Verily Life Sciences LLC